Rituximab-Induced Serum Sickness in a Patient with Pemphigus Vulgaris: A
Case Report
- Mohamad Khatib,
- Solaiman Allafi,
- Abdulqadir Nashwan
![](https://d197for5662m48.cloudfront.net/assets/icons/omniauth/orcid-ca37582cd91a671ed5cec57770e0e96c01b4b79b8b5b75d8598fc1ddac18c974.svg)
Abstract
Serum sickness, a reaction characterized by fever, rash, myalgia, and
arthralgia, can occur in patients who receive chimeric monoclonal
antibody therapy. Serum sickness is considered as a rare adverse event
following rituximab therapy. We report a case of serum sickness in a
newly treated patient with rituximab for pemphigus vulgaris.